secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001437749-25-031572
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC conference
--------------------------------------------------------------------------------

- Reqorsa plus alectinib shrank tumors by 79% vs 60% with alectinib alone in mouse xenograft model.
- QO mediated TUSC2 overexpression induced apoptosis in ALK+ cell lines and patient-derived organoids.
- Combination treatment showed reduced tumor regrowth 2 weeks after end of dosing vs single agents.
- Data support potential clinical trial of Reqorsa for ALK-EML4 positive NSCLC patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925031572/0001437749-25-031572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774925031572/gnpx20251021d_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-031572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer